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Abstract Despite the progress in therapeutic targets, it re-
mains dissatisfactory for most osteosarcoma patients with me-
tastasis or recurrence osteosarcoma. Therefore, it is required to
determine the involvedmechanisms of osteosarcoma. The aim
of this study was to investigate the expression level of MiR-
217 and miR-646 and also their association with clinicopath-
ological features in patients with osteosarcoma. Total RNA
was purified from patients with osteosarcoma and noncancer-
ous bone tissues, and then quantitative real-time PCR was
applied to evaluate the expression level of microRNAs. Our
result suggested that miR-217 expression was remarkably de-
ceased in osteosarcoma bone tissue when compared with non-
cancerous bone tissues (mean±SD 5.32±1.231, 2.01±0.78;
P=0.024) and miR-646 expression decreased in osteosarcoma
bone tissue in comparison with normal tissues (mean±SD
4.56±1.45, 1.76±1.24; P=0.041). Our findings indicated that
decreased expression of MiR-217 and miR-646 was strongly
correlated with high tumor, node, and metastasis (TNM) stage
(P=0.015, P=0.002) and large cancer diameter (P=0.041,P=
0.053). Kaplan-Meier survival and log-rank analysis indicated
that shorter overall survival was strongly linked to decreased
expression of miR-217 and miR-646 (log-rank test P=0.034,
P=0.026). In terms of miR-217, multivariate Cox proportion-
al hazards model analysis has showed that reduction of miR-
217 expression (P=0.001), TNM stage (P=0.046), and lymph
node metastasis (P=0.006) were independently linked to a
short-time survival of patients. In terms of miR-646, low ex-
pression of miR-646 (P=0.021), TNM stage (P=0.052), and
tumor size (P=0.043) were independently associated with
poor survival of patients as prognostic factors. Our findings
suggested that downregulation of MiR-217 and miR-646 was
associated with progression of osteosarcoma. MiR-217 and
miR-646 may play a key role in suppression of tumor in os-
teosarcoma and would be applied as a novel therapeutic agent.
Keywords Osteosarcoma .MiRNAs . Pathology .
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Introduction
Osteosarcoma is known as the most common primary bone
tumor in children and young adults [1, 2]. Despite the progress
in therapeutic targets, it remains dissatisfactory for most oste-
osarcoma patients with metastasis or recurrence osteosarco-
ma. Furthermore, it is required to determine the involved
mechanisms of osteosarcoma. Previous studies have indicated
that microRNA expression may act as a significant marker for
prognosis and detection of cancer. MicroRNAs are known as
small noncoding RNAs [3–5] that act inmany biological func-
tions including cell fate specification, cellular proliferation,
differentiation, and apoptosis through alteration of the targets
expression by both downregulation and upregulation [3, 6, 7].
miRNAs are as either oncogenes or tumor suppressors
in cancers of human [8].
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It is worth noting that dysregulation of different
microRNAs such as miR-34, miR-145, miR-206, miR-33a,
miR-100, and miR-221 has recently been suggested in terms
of osteosarcoma [7, 9–12]. These studies have reported that
microRNAs can play their role as prognostic and diagnostic
markers, as well as they indicated that microRNAs have po-
tential therapeutic targets for osteosarcoma. Therefore, we
evaluated the clinical significance of miR-217 and MiR-182
expression in human osteosarcoma and their association with
clinicopathological features.
Materials and methods
Samples
A total of 41 samples were collected from patients with oste-
osarcoma and corresponding noncancerous bone tissue be-
tween September 2009 and April 2013 in different hospitals
in Tehran, Iran. Patients underwent surgery without chemo-
therapy or radiotherapy. Before the surgery, informed consent
was obtained from each patient. The specimens were stored at
−80 °C until use. Moreover, the diagnosis and the histological
grading were approved by pathologists. The clinicopatholog-
ical features are classified in Table 1.
Table 1 Correlation between microRNA expression and clinicopathological features of patients with osteosarcoma
Characteristic Number miR-217 expression miR-646 expression P value (miR-217) P value (miR-646)
Low High Low High
Gender
Male 17 10 7 12 5 0.674 0.541
Female 24 17 12 15 9
Age
≤60 13 8 5 7 4 0.563 0.512
>60 28 11 17 13 15
Tumor size (cm)
≤5 26 11 15 16 10 0.041 0.053
>5 15 13 2 8 7
Lymph node metastasis
Negative 34 16 19 14 20 0.126 0.102
Positive 7 4 3 5 2
Histologic grade/differentiation
Well and moderate 19 11 8 13 6 0.243 0.214
Poor 22 13 9 12 10
TNM stage
I+II 11 3 8 4 7 0.015 0.002
III+IV 30 24 6 22 8
Fig. 1 The relative expression level of MiR-217 expression between
osteosarcoma bone tissue and noncancerous bone tissues
Fig. 2 The relative expression level of MiR-646 expression between
osteosarcoma bone tissue and noncancerous bone tissues
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Quantitative real-time PCR
In the present study, the total RNAwas purified from samples
of noncancerous bone tissue using TRIzol reagent based on
the constructor’s instructions for user. Gene-specific primers
were used to synthesize cDNA from the TaqMan microRNA
Assays and reagents from the TaqMan microRNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA,
USA). Furthermore, real-time PCR was carried out using an
Invitrogen kit by system of Rotor-gene 6000 (Qiagen). The
primers were used from the TaqMan miRNA assays. More-
over, an internal standard control was applied (small nucleolar
RNA U6). The ΔΔCt (ΔΔCt=ΔCttumor samples−ΔCtcontrol
sample) to qualify the expression rate of miR-217 and
miR-1646.
Statistical analysis
Obtained data were analyzed using SPSS 16.0 software (SPSS
Inc., USA). Differences between all variables were evaluated
using Student’s t test or chi-square test. Moreover, survival
evaluation was done by applying the log-rank test and
Kaplan-Meier method. A Cox proportional hazards model
was performed to assess multivariate analyses of prognostic
values. Differences were statistically significant at P<0.05.
Results
Our result suggested that miR-217 expression was remarkably
deceased in osteosarcoma bone tissue when compared with
noncancerous bone tissues (mean±SD 5.32±1.231, 2.01±
0.78; P=0.024; Fig. 1), Furthermore, miR-646 expression
was downregulated in osteosarcoma bone tissue in compari-
son with normal tissues (mean±SD 4.56±1.45, 1.76±1.24;
P=0.041; Fig. 2). Osteosarcoma patients were categorized
into two groups (low and high group) based on the median
expression level of miR-217 and miR-646. The clinicopatho-
logical features of microRNAs in high and low expression
groups were compared (Table 1).
The results of the current study indicated that decreased
expression of MiR-217 and miR-646 was strongly correlated
with high tumor, node, andmetastasis (TNM) stage (P=0.015,
P=0.002) and large cancer diameter (P=0.041, P=0.053).
However, there were no significant relationships of MiR-217
and miR-646 expression with other factors including age (P=
0.563, P=0.512), sex (P=0.674, P=0.541), anatomic location
Fig. 3 Correlation between miR-217 expression and survival time in
patients with osteosarcoma
Fig. 4 Correlation between miR-646 expression and survival time in
patients with osteosarcoma
Table 2 Multivariate analysis with a Cox proportional hazards model
between miR-217 and clinicopathological factors
Clinicopathological characteristics HR 95 % CI P value
Gender 0.742 0.672–2.341 0.623
Age 1.46 0.758–2.483 0.542
TNM stage 2.32 1.635–4.785 0.046
Tumor size (cm) 0.86 1.567–2.416 0.475
Histological grading 0.96 1.218–2.763 0.324
Lymph node metastasis 1.636 1.326–4.824 0.006
miR-217 level 2.724 1.619–5.427 0.001
Table 3 Multivariate analysis with a Cox proportional hazards model
between miR-646 and clinicopathological features
Clinicopathological characteristics HR 95 % CI P value
Gender 0.638 0.364–2.721 0.562
Age 0.85 0.437–2.462 0.516
TNM stage 2.42 1.749–4.932 0.052
Tumor size (cm) 2.75 0.573–4.936 0.043
Histological grading 0.86 1.521–2.428 0.317
Lymph node metastasis 1.012 1.12–2.927 0.143
miR-646 level 2.823 1.624–5.424 0.021
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(data not seen), (P=0.316, P=0.415), histologic grade/
differentiation (P=0.243, P=0.214), and lymph node metas-
tasis (P=0.126, P=0.102 (Table 1). Kaplan-Meier survival
and log-rank analysis indicated that shorter overall survival
was remarkably correlated with decreased expression of
MiR-217 and miR-646 (log-rank test P=0.034, P=0.026;
Figs. 3 and 4).
In terms of miR-217, multivariate Cox proportional haz-
ards model analysis showed that low expression of miR-217
(P=0.001), TNM stage (P=0.046), and lymph node metasta-
sis (P=0.006) was independently associated with poor surviv-
al of patients as prognostic factors (Table 2). In terms of miR-
646, low expression of miR-646 (P=0.021), TNM stage (P=
0.052), and tumor size (P=0.043) were independently associ-
ated with poor survival of patients as prognostic factors
(Table 3).
Discussion
MiRNAs are either oncogenes or tumor suppressors in human
carcinogenesis [8]. Dysregulation of microRNAs has been
previously reported in many kinds of tumor. Moreover, dys-
regulation of different miRNAs has been recently suggested in
terms of osteosarcoma [7, 9–11]. It has been suggested that
there is a correlation between miRNA expressions and tumor
prognosis [13, 14]. Furthermore, determination of functional
and clinical importance of a specific miRNA may provide
effective management of the disease. In the current study,
we evaluated the clinical significance of miR-217 and MiR-
646 expression in human osteosarcoma.
Our result suggested that miR-217 expression was remark-
ably deceased in osteosarcoma bone tissue when compared
with noncancerous bone tissues. This finding indicated that
miR-217 can contribute to tumor occurrence and develop-
ment. Dysregulation of miR-217 expression has been previ-
ously reported in much kind of human malignancies as a tu-
mor suppressor. Zhao et al. indicated that miR-217 plays its
role in the suppression of tumor by targeting the KRAS onco-
gene in pancreatic ductal adenocarcinoma [15]. On the other
hand, upregulation of miR-217 was strongly reported in he-
patocellular carcinoma (HCC) patients and also cell. Other
study indicated that upregulation of the miR-217 could be
linked to estrogen receptor status [16] and could have an im-
portant positive role in the progression of breast cancer. It can
be interpreted that miR-217 may act as tissue specific. It has
been suggested that miR-217 can be tumor specific and prob-
ably dependent on its targets in many kinds of cancer.
On the other hand, miR-646 expressionwas downregulated
in osteosarcoma bone tissue in comparison with normal tis-
sues in the current study. It has been reported that miR-646
downregulated in many cancer types [17], and increasing ev-
idence suggests that it can play a key role as a tumor
suppressor. Li et al suggested that miR-646 was decreased in
renal cancer that was remarkably linked to metastasis of tumor
via the MAPK pathway by targeting NOB1 [18]. Our result
indicated that low expression ofMiR-217 andmiR-646 can be
associated with tumor progression in osteosarcoma. Study re-
sults of Shen et al. demonstrate that miR-217 functions as a
tumor-suppressive miRNA and inhibits the osteosarcoma tu-
morigenesis through targetingWASF3. In anoother study, Sun
et al. demonstrated that miR-646 might be a tumor suppressor
in osteosarcoma via the regulation of FGF2, which provided a
potential prognostic biomarker and therapeutic target [19, 20].
The results of the current study indicated that decreased
expression of MiR-217 and miR-646 was strongly correlated
with high TNM stage and large tumor diameter that could be
associated with tumor progression. Kaplan-Meier survival and
log-rank analysis indicated that shorter overall survival was
strongly linked to decreased expression of MiR-217 and miR-
646, indicating that MiR-217 and miR-646 may be markers
for prognosis in patients that suffered osteosarcoma.
In terms of miR-217, multivariate Cox proportional haz-
ards model analysis showed that low expression of miR-217,
TNM stage, and lymph node metastasis were independent
prognostic factors for poor survival of patients. In terms of
miR-646, low expression of miR-646, TNM stage, and tumor
size were independently associated with poor survival of pa-
tients as prognostic factors.
In conclusion, our findings suggested that downregulation
of miR-217 and miR-646 was associated with progression of
osteosarcoma. MiR-217 and miR-646 may play a key role in
suppression of tumor in osteosarcoma and likely would be
applied as novel therapeutic agents.
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